JP4546090B2 - Ｉｍｐｄｈ酵素のアクリドンインヒビター - Google Patents

Ｉｍｐｄｈ酵素のアクリドンインヒビター Download PDF

Info

Publication number
JP4546090B2
JP4546090B2 JP2003559434A JP2003559434A JP4546090B2 JP 4546090 B2 JP4546090 B2 JP 4546090B2 JP 2003559434 A JP2003559434 A JP 2003559434A JP 2003559434 A JP2003559434 A JP 2003559434A JP 4546090 B2 JP4546090 B2 JP 4546090B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
mmol
compound
heterocyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003559434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514434A (ja
Inventor
エドウィン・ジェイ・イワノウィッツ
スコット・エイチ・ワッターソン
チェン・ピン
ティ・ジー・ムラリ・ダー
グ・ヘンリー・エイチ
ジャオ・ユフェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2005514434A publication Critical patent/JP2005514434A/ja
Application granted granted Critical
Publication of JP4546090B2 publication Critical patent/JP4546090B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003559434A 2001-12-21 2002-12-20 Ｉｍｐｄｈ酵素のアクリドンインヒビター Expired - Fee Related JP4546090B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34323401P 2001-12-21 2001-12-21
PCT/US2002/041530 WO2003059269A2 (en) 2001-12-21 2002-12-20 Acridone inhibitors of impdh enzyme

Publications (2)

Publication Number Publication Date
JP2005514434A JP2005514434A (ja) 2005-05-19
JP4546090B2 true JP4546090B2 (ja) 2010-09-15

Family

ID=23345248

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003559434A Expired - Fee Related JP4546090B2 (ja) 2001-12-21 2002-12-20 Ｉｍｐｄｈ酵素のアクリドンインヒビター
JP2003556025A Expired - Fee Related JP4601293B2 (ja) 2001-12-21 2002-12-20 Ｉｍｐｄｈ酵素のヘテロ環アクリドンインヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003556025A Expired - Fee Related JP4601293B2 (ja) 2001-12-21 2002-12-20 Ｉｍｐｄｈ酵素のヘテロ環アクリドンインヒビター

Country Status (13)

Country Link
US (2) US6916809B2 (https=)
EP (2) EP1456207A4 (https=)
JP (2) JP4546090B2 (https=)
AT (1) ATE441414T1 (https=)
AU (2) AU2002360797A1 (https=)
DE (1) DE60233592D1 (https=)
ES (1) ES2330839T3 (https=)
HU (2) HUP0500163A3 (https=)
PE (1) PE20030894A1 (https=)
PL (2) PL373672A1 (https=)
TW (1) TW200301698A (https=)
UY (1) UY27597A1 (https=)
WO (2) WO2003055447A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
CN1934091B (zh) 2004-03-23 2012-02-08 辉瑞产品公司 治疗神经变性障碍的咪唑化合物
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
WO2006068978A2 (en) * 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
WO2006078576A2 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
EP1899294B1 (en) * 2005-06-13 2015-03-18 Merck Sharp & Dohme Limited Therapeutic agents
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
WO2007034326A2 (en) 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
EP1951220A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
WO2007109363A2 (en) * 2006-03-20 2007-09-27 The Johns Hopkins University Methods and compositions for inhibiting impdh isoform 1
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EP2068112A4 (en) 2006-09-29 2017-11-15 Nikon Corporation Mobile unit system, pattern forming device, exposing device, exposing method, and device manufacturing method
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CA2673290A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
MX2011002448A (es) * 2008-09-05 2011-05-25 Acucela Inc Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
TW201116212A (en) 2009-10-29 2011-05-16 Du Pont Heterobicycle-substituted azolyl benzene fungicides
CA2923835C (en) * 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
JP6553632B2 (ja) 2013-11-18 2019-07-31 フォーマ セラピューティクス，インコーポレイテッド Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. CALPAIN MODULATORS AND THERAPEUTIC USE THEREOF
BR112019006110A2 (pt) 2016-09-28 2019-09-10 Blade Therapeutics Inc moduladores de calpaína e usos terapêuticos dos mesmos
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
KR20220016086A (ko) * 2019-05-03 2022-02-08 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
CN110563643A (zh) * 2019-10-14 2019-12-13 常州齐晖药业有限公司 一种(5-溴-3-甲基-吡啶-2-基)-甲胺的合成方法
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
JP7699836B2 (ja) 2020-02-28 2025-06-30 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｋｃｎｔ１阻害剤、および使用方法
US20230285376A1 (en) 2020-07-29 2023-09-14 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
CN117510403A (zh) * 2022-07-29 2024-02-06 阿里生物新材料（常州）有限公司 一种3-乙基-吡啶-2-甲脒盐酸盐的合成方法
CN115557890B (zh) * 2022-09-01 2024-06-25 宁波大学 一种多取代吖啶酮烷基衍生物及其制备方法和用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2120154B1 (https=) * 1970-12-30 1975-08-29 Tekkosha Co
US3987088A (en) * 1971-09-08 1976-10-19 Burroughs Wellcome Co. Cyclic carbonyl compounds
US4061768A (en) * 1971-09-08 1977-12-06 Burroughs Wellcome Co. Certain cyclic carbonyl compounds used in the prophylaxis of allergic conditions
US3950342A (en) * 1971-09-08 1976-04-13 Burroughs Wellcome Co. Acridone-dicarboxylic acids
LU66018A1 (https=) 1971-09-08 1973-03-12
PH9949A (en) 1972-02-24 1976-06-14 J Gorvin Compositions containing cyclic carbonyl compounds
US4250182A (en) * 1972-02-24 1981-02-10 Burroughs Wellcome Co. Pharmaceutical composition containing acridone compounds and method of using same
US3835139A (en) * 1972-07-19 1974-09-10 Syntex Inc N-substituted acridone carboxylic acids and derivatives
JPS55122781A (en) * 1979-01-24 1980-09-20 Warner Lambert Co Substitued pyrazolo*5*11b*quinazolinee9*4h**one compound
US4247555A (en) * 1980-01-11 1981-01-27 Warner-Lambert Company 4,9-Dihydro-9-oxo-N-1H-tetrazol-5-yl-pyrazolo[5,1-b]-quinazoline-2-carboxamides and antiallergic compositions and methods using them
US4261997A (en) * 1980-01-11 1981-04-14 Warner-Lambert Company 4-Alkyl-pyrazolo[5,1-b]-quinazolin-9(4H)-ones and anti-allergic compositions containing them
DE3008411A1 (de) * 1980-03-05 1981-09-10 Merck Patent Gmbh, 6100 Darmstadt Neue aromatisch-aliphatische ketone, ihre verwendung als photoinitiatoren sowie photopolymerisierbare systeme enthaltend solche ketone
DE3049405A1 (de) 1980-12-23 1982-07-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue derivate von antiphlogistisch wirksamen carbonsaeuren, ihre herstellung und medizinische anwendung
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4861776A (en) * 1987-01-30 1989-08-29 Syntex (U.S.A) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof, compositions and use
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
JPH0733485B2 (ja) * 1987-06-05 1995-04-12 東洋インキ製造株式会社 顔料分散剤
JPH0786676B2 (ja) * 1987-12-28 1995-09-20 コニカ株式会社 新規なカラー写真用シアンカプラー
JP2673809B2 (ja) * 1988-02-15 1997-11-05 コニカ株式会社 新規な写真用カプラー
US5665583A (en) * 1988-08-12 1997-09-09 Arch Dev Corp Methods and materials relating to IMPDH and GMP production
US5342942A (en) * 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
WO1994012184A1 (en) 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JPH10158261A (ja) * 1996-03-05 1998-06-16 Takeda Chem Ind Ltd キサンテン誘導体、その製造法および用途
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
CA2267500A1 (en) 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
JPH10123684A (ja) * 1996-10-21 1998-05-15 Konica Corp ハロゲン化銀写真感光材料
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
US5998454A (en) * 1997-03-21 1999-12-07 Eli Lilly And Company Leukotriene antagonists useful for treating iritis
JPH11130767A (ja) 1997-10-28 1999-05-18 Toray Ind Inc ラクトン誘導体およびその医薬用途
WO2000023416A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6353018B1 (en) 1998-10-21 2002-03-05 Novo Nordisk A/S Compounds, their preparation and use
GB0113435D0 (en) 2001-06-04 2001-07-25 Amersham Pharm Biotech Uk Ltd Acridone derivatives as labels for fluorescence detection of target materials
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
EP1458392B1 (en) 2009-09-02
EP1456207A2 (en) 2004-09-15
WO2003059269A3 (en) 2003-12-31
PL373672A1 (en) 2005-09-05
AU2002360797A1 (en) 2003-07-30
UY27597A1 (es) 2003-07-31
AU2002361848A8 (en) 2003-07-15
US6916809B2 (en) 2005-07-12
EP1458392B9 (en) 2010-07-28
HUP0500574A2 (hu) 2005-11-28
WO2003055447A3 (en) 2004-01-22
JP2005514434A (ja) 2005-05-19
US20030181497A1 (en) 2003-09-25
HUP0500163A2 (hu) 2005-05-30
WO2003055447A2 (en) 2003-07-10
DE60233592D1 (de) 2009-10-15
EP1458392A2 (en) 2004-09-22
HUP0500163A3 (en) 2012-07-30
US7312209B2 (en) 2007-12-25
ATE441414T1 (de) 2009-09-15
EP1456207A4 (en) 2005-06-01
WO2003059269A2 (en) 2003-07-24
PL371348A1 (en) 2005-06-13
ES2330839T3 (es) 2009-12-16
JP4601293B2 (ja) 2010-12-22
TW200301698A (en) 2003-07-16
PE20030894A1 (es) 2003-10-23
US20040053955A1 (en) 2004-03-18
AU2002361848A1 (en) 2003-07-15
AU2002360797A8 (en) 2003-07-30
HUP0500574A3 (en) 2008-03-28
EP1458392A4 (en) 2005-06-08
JP2005514398A (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
JP4546090B2 (ja) Ｉｍｐｄｈ酵素のアクリドンインヒビター
JP5123949B2 (ja) 非ヌクレオシド逆転写酵素阻害剤
JP5406039B2 (ja) タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
WO2021087018A1 (en) Pyridazinones as parp7 inhibitors
AU2019283921A1 (en) Indole carboxamide compounds useful as kinase inhibitors
JP2005521698A (ja) 新規な三環式化合物
WO2013085802A1 (en) Pyrrolopyrimidines as janus kinase inhibitors
SG186773A1 (en) 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors
CA2750051A1 (en) Inhibitors of akt activity
JP2014062123A (ja) Ｉｄｏ阻害剤
WO2001081340A2 (en) Heterocycles that are inhibitors of impdh enzyme
AU2001255538A1 (en) Heterocycles that are inhibitors of IMPDH enzyme
US9266880B2 (en) Substituted azaindazole compounds
CN115991706A (zh) Pim激酶抑制剂
US11136321B2 (en) Tricyclic compounds
CN114981256B (zh) 干扰素基因刺激物sting的单环激动剂
US6974815B2 (en) Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
TW202423921A (zh) 稠合的雜雙環抗病毒劑
JP3012338B2 (ja) アリールおよびヘテロアリールアルコキシナフタレン誘導体
JP2008523155A (ja) ピリジル置換スピロ−ヒダントイン化合物およびその使用
JP7143437B2 (ja) Ｆｍｓ様チロシンキナーゼ阻害剤
US20220000874A1 (en) Tricyclic compounds

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090903

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090907

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100629

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100701

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130709

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees